Abstract
INTRODUCTION
Hepatocellular carcinoma (HCC) ranks sixth and third worldwide in tumor incidence and mortality, res pectively [1] . Despite dramatic improvements in surgical treatment and chemotherapy, the oneyear survival rate of patients diagnosed with HCC is not high [2, 3] . In addition, traditional chemotherapy drugs have obvious side effects. Therefore, seeking an effective drug treatment that reduces the mortality of patients with HCC is of great significance.
Dihydromyricetin (DHM, C15H12O8, PubChem CID: 161557) is a component of wild woody vines of the genus Vitis, which is a flavonoid compound [4] . DHM was reported to have antioxidant [5, 6] , antiinflammatory [7] , antihypertensive [8] , hypoglycemic [9] , hepatopro tective [10, 11] , and anticarcinogenic effects [12] . Previous studies have reported that DHM can inhibit the invasion and metastasis of HCC cells [13] . Combined application of DHM and nedaplatin induced apoptosis of HCC cells through the p53/Bcl2 pathway, and enhanced sensitivity to nedaplatin chemotherapy [14] . DHM has great potential as a treatment option for liver cancer.
The Notch signaling pathway plays an important role in the fate of many cells and is crucial for the biological development of embryos. The Notch pathway is composed of a transmembrane family of receptors (Notch 14) , their ligands (Jagged 12, Deltalike 13), and downstream target genes in the HES and HEY protein families [15] . Notch receptors bind to ligands in the membranes of adjacent cells, causing the intra cellular segment of the Notch receptor to release, and the receptor then travels to the nucleus, resulting in activation of Notch target genes, thus successfully mediating cell growth and development [16] . Studies of Notch and liver diseases have been conducted in recent years. Notch3 is highly expressed in HCC, can promote the selfrenewal of HCC cells and plays a significant role in maintaining stem cells by downregulating βcatenin and upregulating the expression of Nanog [17] . High expression of Notch1 and Notch4 is closely associated with poor prognosis of patients with HCC [18] . Suppression of the Notch signaling pathway averts cholestatic liver fibrosis by lessening the differentiation of hepatic progenitor cells into cholangiocytes [19] . Inhibition of Notch1 expression promoted pancreatic cancer and prostate cancer cell apoptosis [20, 21] , but whether downregulation of Notch1 induces apoptosis in hepatoma cells has rarely been reported. Moreover, the antitumor activity of DHM and its regulation of the Notch pathway are still unclear.
In the present study, we demonstrated that aberrant Notch1 expression was involved in tumor progression. DHM could downregulate the expression of Notch1 to induce apoptosis in HepG2 and QGY7701 HCC cells and restrain their proliferation. Inhibition of Notch1 signaling may serve as a novel target for HCC treatment. 
MATERIALS AND METHODS

Reagents and chemicals
Clinical specimens
All patients were diagnosed with pathological primary HCC. Tissue samples were obtained from these patients during hepatectomy surgery. HCC was confirmed by pathology. All tissue samples were frozen in liquid nitrogen. This study was approved by the Medical Ethics Committee of the Affiliated Hospital of Guangdong Medical University.
Cell lines and cell culture
The cells (SKHep1, QGY7703, MHCC97L, HepG2, QGY7701 and HL7702) were maintained in DMEM supplemented with 10% fetal bovine serum and antibiotics (penicillin and streptomycin) in a humidified 5% CO2 incubator. Upon reaching 80% confluence, the cells were treated with various concentrations of DHM (0, 5, 25, 50, 100 or 150 μmol/L) for 12 h, 24 h and 36 h and DMSO treatment served as a control.
Cell inhibition and cytotoxicity assay
The cells were placed into 96well plates and treated with different concentrations of DHM. DMSO treatment served as a control. Twenty μL of MTT (5 mg/mL) solution was transferred to each well, and then the plate was incubated at 37 ℃ for 4 h. Next, the cell supernatants were removed, and 150 μL of DMSO was added to each well to solubilize the formed crystals. The optical density values were measured at 570 nm with a spectrophotometer (PerkinElmer, the United States of America).
Apoptosis assay
The HepG2 and QGY7701 cells were seeded in the 6well plates. Following overnight growth, the cells were pretreated with 50, 100, or 150 μmol/L DHM and incubated for 24 h. Following careful collection and suspension in binding buffer, the HepG2 and QGY7701 cells were incubated with 5 mL of annexin VFITC and 5 mL of PI for 15 min in darkness prior to flow cytometric analysis.
Western blot
The tissues protein samples were prepared with Fastprep24 Sample Preparation equipment (MP, United States). The cells treated with DHM were harvested and lysed in lysis buffer to assess the expression of Notch1, Hes1, Bcl2 and Bax. Equal amounts of protein samples were loaded per well. Membranes containing protein blots were incubated in blocking buffer (5% nonfat milk) for 1 h at room temperature, and then the membranes were incubated with the primary antibodies (1:1000 dilution) at 4 ℃ overnight. Following a wash with TBST, membranes were incubated with goat anti rabbit secondary antibodies for 1 h. Detection was performed using an Odyssey Infrared Imaging System (LICOR Biosciences Inc., Lincoln, NE, the United States of America).
qRT-PCR analysis
Frozen tissues were used to isolate messenger RNA (mRNA) using TRIzol reagent (Invitrogen, Guangzhou, China), according to the manufacturer's protocol. Reverse transcription was performed with 1 μg of RNA using the PrimeScript RT Reagent kit with a gDNA Eraser kit (Takara Bio, Inc, Otsu, Japan). The primer sequences used were as follows: Notch1 forward, 5'CACCCATGACCACTACCCAGTT3' and reverse, 5'CCTCGGACCAATCAGAGATGTT3'; Hes1 forward, 5'AGATCTATGCCAGCTGATAAT3'and reverse, 5'AAGCTTCACTTAATACAGCT3', and 18s forward, 5'CGGCGACGACCCATTCGAAC3' and reverse, 5'GAATCGAACCCTGATTCCCCGTC3'. Data were evaluated using the comparative count method and normalized to the corresponding 18S value.
TUNEL assay
In situ cell death detection kitPOD (Roche, Switzerland) was used to detect the latestage apoptosis. Cells were seeded in 96well plates and treated with various concentrations of DHM. Cells were fixed with 4% paraformaldehyde, and then counterstained with 4',6diamidino2phenylindole for 5 min at room temperature in the dark and observed under a fluorescence microscope (Olympus IX70, Japan) to detect the apoptotic cells.
siRNA transfection
QGY7701 and HepG2 cells were plated into 6well plates and transfection procedures were performed according to the manufacturer's protocol. Three different Notch1 siRNA sequences were tested in both QGY7701 and HepG2 cell lines for screening the efficacy of Notch1 knockdown and selecting the best performing siRNA transcript. Notch1 siRNA2 showed the best degree of knockdown and was used in subsequent experiments. Before each experiment, we transiently transfected cells using an Notch1 siRNA gene knockdown kit (JIMA Biotechnology Company, Shanghai, China) and the negative control siRNA.
Colony formation assay
Cells in each logarithmic growth phase were detached from culture flasks using 0.25% trypsin. Then, the cells were percussed into a single cell suspension, and 1000 cells were cultured in each well of a 6well plate, and humidity was saturated for 1 wk. The cells were stained with crystal violet. Clones were directly counted by the naked eye or counted using a microscope, and with the control group ( Figure 2E ). A colony formation assay was utilized to further determine the proliferative ability of cells treated with various concentrations of DHM, and similarly, DHM suppressed colonyforming capability in a dosedependent manner ( Figure 2FH ).
DHM induces apoptosis in HCC cells
Flow cytometry revealed that apoptosis was induced in HepG2 and QGY7701 cell lines following 24 h of DHM treatment ( Figure 3AC ). A TUNEL assay was utilized to detect latestage apoptosis of the cell lines treated with various concentrations of DHM for 24 h. In the fluorescence images, there were cells in latestage apoptosis in both the HepG2 and QGY7701 cell lines ( Figure 3DF ).
Effects of DHM treatment on proteins in the Notch1 pathway and on apoptosis-related proteins in HCC cells
In this study, Notch1, Hes1 and apoptosisrelated proteins were detected by Western blotting. The results demonstrated that DHM downregulated the expression of Notch1 and Hes1 in QGY7701 and HepG2 cells. Meanwhile, Bax was upregulated, and Bcl2 was downregulated. The results suggested that downregulation of Notch1 activated the mitochondrial apoptotic pathway ( Figure 4A and C). It is known that a lower ratio of Bcl2/Bax leads to apoptosis, and our data showed that the ratio of Bcl2/Bax was reduced ( Figure  4B and D).
DHM induces apoptosis in HCC cells by downregulating the Notch1 pathway
To further elucidate whether the inhibition of proli feration and the promotion of apoptosis of QGY7701 and HepG2 cells were caused by the downregulation of Notch1 following DHM treatment, siRNA was used to silence Notch1 expression, and Notch1silenced cells were treated with DHM. The knockout efficiency of the three different Notch1 siRNA sequences is shown in Figure 5A . The expression levels of Notch1, Hes1 and the apoptotic proteins Bcl2 and Bax were analyzed by Western blot. Compared with the control group, Bax was upregulated, and Hes1 and Bcl2 were downregulated after the depletion of Notch1 via siRNA. The results were consistent with the DHM 100 μmol/L treatment group. However, the effect of the Notch1 siRNA and DHM 100 μmol/L combination on protein expression was more obvious (Figure 5B and D) . As expected, the ratio of Bcl2/Bax decreased the most in the Notch1siRNA + DHM 100 μmol/L group ( Figure 5C and E). In summary, DHM exerted antitumor activity by downregulating the expression of Notch1.
DISCUSSION
As a multifunctional protein, Notch1 plays a role in regu lating cell differentiation, development, proliferation and survival in various contexts [15, 16] . Abnormal expre ssion of Notch1 often leads to tumors. For example, data were analyzed using ImageJ software.
Statistical analysis
The data were obtained from at least three independent experiments, and all results are presented as the mean ± SD. The results were evaluated using Student's t test, Pearson correlation analyses were used to examine the correlation of two parameters. The significance levels were defined as P < 0.05.
RESULTS
Notch1 expression is activated in HCC tissues and reflects differentiation properties
The expression of Notch1 protein by Western blots and found that Notch1 accumulated predominantly in HCC tissues ( Figure 1A ). In addition, the expression of Notch1 and Hes1 genes in HCC and normal liver tissue samples was analyzed by qRTPCR ( Figure 1B and C) . Among the tested samples (n = 64), the expression levels of Notch1 (75% of patients) and Hes1 (79.7% of patients) mRNA in tumor tissues were higher than in the normal liver tissues ( Figure 1D) . A positive corre lation between Notch1 and Hes1 expression suggests that high expression of Notch1 in tumors may result in an upregulation of the target gene Hes1 ( Figure  1E ). To clarify the role of Notch1 in tumorigenesis and tumor differentiation, we analyzed the association among Notch1 expression, AFP concentration, and the degree of tumor differentiation. There was a negative correlation between the expression of Notch1 and the degree of differentiation and a positive correlation with the AFP concentration ( Figure 1F and G) . The results showed that Notch1 was highly expressed in tumor cells with higher degrees of malignancy and proliferative activity. Based on the results above, Notch1 was involved in the development and progression of HCC.
DHM inhibits the proliferation of HCC cells
We also screened the Notch1 protein expression profiles in several hepatoma cell lines. Notch1 ex hibited higher expression levels in hepatoma cells compared with the immortalized normal liver cell line HL7702 ( Figure 2B ). Among the hepatoma cell lines, we found that QGY7701 and HepG2 cells highly express Notch1. Therefore, we chose these two lines for the next experiment. MTT assays showed that the proliferation of DHMtreated QGY7701 and HepG2 cells was inhibited. After 12 h, 24 h and 36 h, the viability of HCC cells treated with DHM was significantly inhibited in a dose and timedependent manner ( Figure 2C and  D) . As shown in Figure 2 , the proliferation of cells was significantly inhibited after treatment with 150 μmol/L and 50 μmol/L DHM for 12 h (P < 0.01), and the cell viability of both QGY7701 and HepG2 cells treated with 50 μmol/L DHM for 48 h and 25 μmol/L DHM for 24 h was significantly inhibited (P < 0.001). The microscopy suggested that the proliferation of the two cell lines was inhibited and partial apoptosis occurred compared in pancreatic cancer, colon cancer, nonsmall cell lung cancer, cervical cancer and other tumors, Notch1 expression is increased, and Notch1 participates in the promotion of cell proliferation, inhibition of apoptosis and cellular differentiation [2224] . Overexpression of Hes1 has also been reported in the development of HCC [17] . Western blotting and qRTPCR analysis of clinical HCC samples indicated that Notch1 and Hes1 were highly expressed in tumor samples, and the expression rates of Notch1 and Hes1 accounted for 75% and 79.7% of the total data, respectively. The above results show that Notch1mediated activation of Notch signaling is a hallmark of HCC. This further explains the correlation among Notch1 expression, AFP (a clinical diagnostic marker of HCC) expression, and the degree of differentiation. The expression of Notch1
Lu CJ et al . DHM induces hepatoma cell apoptosis by inhibiting Notch1 Hes1   GAPDH   1  1  2  2  3  3  4  4  5  5  6  6  7  7 This indicated that Notch1 is highly expressed in tumor cells with higher degrees of malignancy and proliferative activity. Experienced clinicians frequently find that tumors with higher growth activity seem to be more susceptible to chemotherapeutic treatment. These facts suggest that Notch1 is involved in the development of HCC and Notch1 may be a potential diagnostic indicator of HCC and target for chemotherapeutic treatment.
The inhibition of cell proliferation and promotion of apoptosis are common targets by many chemo therapeutic agents [25] . DHM inhibits the proliferation of diverse types of cells, including osteosarcoma, melanoma, leukemia and gastric cancer cells [2629] . Many molecules and signaling pathways are involved in the antitumor effect of DHM, including the Chk1/ Chk2/Cdc25C pathway [29] , the NFκB and MAPK signaling pathways [7] , and the transforming growth factorβ pathway [30] . Nevertheless, the effect of DHM Lu CJ et al . DHM induces hepatoma cell apoptosis by inhibiting Notch1 24 h; E and F: Apoptosis was quantified and presented as a statistical figure; Each experiment was repeated more than three times; a P < 0.05, b P < 0.01, c P < 0.001 vs 0 μmol/L (control) group; e P < 0.05, d P < 0.01, f P < 0.001 vs 50 μmol/L group. expression of Notch1 in HCC samples, we examined the effect of various concentrations of DHM on the expression of Notch1, and found that Notch1 and Hes1 were downregulated. Bcl2 and Bax proteins play major roles in the regulation of mitochondriamediated apoptosis, which is a common apoptosis pathway. The Bcl2 (proapoptotic protein) and Bax (antiapoptotic protein) ratio can further reflect the antiapoptotic tendencies. The ratio of antiapoptotic to proapoptotic molecules, such as the Bcl2/Bax ratio, indicates the threshold sensitivity of cells to the induction of apoptosis via the intrinsic (mitochondriamediated) pathway [31, 32] . The data showed that Bcl2 and Bax were downregulated in DHMtreated QGY7701 and HepG2 cells, and the Bcl2/Bax ratio was also decreased. Additionally, we knocked out the expression of Notch1 and treated these Notch1-deficient cells with DHM. The results showed that the effects of Notch1 silencing and DHM treatment were not different. However, when used in combination, Bcl2 was downregulated, Bax was upregulated, and the reduction in the ratio of Bcl2/Bax was more significant. These results show that the antitumor capacity of DHM in the QGY7701 and HepG2 hepatocarcinoma cell lines is partially exerted through inhibition of the Notch1 pathway.
In summary, our experiments confirmed that Notch1 is involved in the development of HCC and may serve as a potential diagnostic marker for HCC and an indicator of malignancy. DHM inhibits cell proliferation and promotes apoptosis by downregulating the ex pression of Notch1, indicating that it can be used as a candidate drug for the treatment of HCC.
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